Related Experiment Video
Updated: Aug 17, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
Rational development of histone deacetylase inhibitors as anticancer agents: a review
Milin R Acharya1, Alex Sparreboom, Jürgen Venitz
1Clinical Pharmacology Research Core, National Cancer Institute, Bethesda, MD 20892, USA.
Abstract:
The epigenome is defined by DNA methylation patterns and the associated post-translational modifications of histones. This histone code determines the expression status of individual genes dependent upon their localization on the chromatin. The histone deacetylases (HDACs) play a major role in keeping the balance between the acetylated and deacetylated states of chromatin and eventually regulate gene expression. Recent developments in understanding the cancer cell cycle, specifically the interplay with chromatin control, are providing opportunities for developing mechanism-based therapeutic drugs. Inhibitors of HDACs are under considerable exploration, in part because of their potential roles in reversing the silenced genes in transformed tumor cells by modulating transcriptional processes. This review is an effort to summarize the nonclinical and clinical status of HDAC inhibitors currently under development in anticancer therapy.
Related Concept Videos
Inhibition of Cdk Activity
Spreading of Chromatin Modifications
Writers
The writer is an enzyme that can...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Abnormal Proliferation
Drugs that Destabilize Microtubules
Histone Variants at the Centromere

